Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

24 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Targeting the PTTG1 oncogene impairs proliferation and invasiveness of melanoma cells sensitive or with acquired resistance to the BRAF inhibitor dabrafenib.
Caporali S, Alvino E, Lacal PM, Ruffini F, Levati L, Bonmassar L, Scoppola A, Marchetti P, Mastroeni S, Antonini Cappellini GC, D'Atri S. Caporali S, et al. Among authors: antonini cappellini gc. Oncotarget. 2017 Dec 9;8(69):113472-113493. doi: 10.18632/oncotarget.23052. eCollection 2017 Dec 26. Oncotarget. 2017. PMID: 29371923 Free PMC article.
miR-126-3p down-regulation contributes to dabrafenib acquired resistance in melanoma by up-regulating ADAM9 and VEGF-A.
Caporali S, Amaro A, Levati L, Alvino E, Lacal PM, Mastroeni S, Ruffini F, Bonmassar L, Antonini Cappellini GC, Felli N, Carè A, Pfeffer U, D'Atri S. Caporali S, et al. Among authors: antonini cappellini gc. J Exp Clin Cancer Res. 2019 Jun 21;38(1):272. doi: 10.1186/s13046-019-1238-4. J Exp Clin Cancer Res. 2019. PMID: 31227006 Free PMC article.
Soluble CTLA-4 as a favorable predictive biomarker in metastatic melanoma patients treated with ipilimumab: an Italian melanoma intergroup study.
Pistillo MP, Fontana V, Morabito A, Dozin B, Laurent S, Carosio R, Banelli B, Ferrero F, Spano L, Tanda E, Ferrucci PF, Martinoli C, Cocorocchio E, Guida M, Tommasi S, De Galitiis F, Pagani E, Antonini Cappellini GC, Marchetti P, Quaglino P, Fava P, Osella-Abate S, Ascierto PA, Capone M, Simeone E, Romani M, Spagnolo F, Queirolo P; Italian Melanoma Intergroup (IMI). Pistillo MP, et al. Among authors: antonini cappellini gc. Cancer Immunol Immunother. 2019 Jan;68(1):97-107. doi: 10.1007/s00262-018-2258-1. Epub 2018 Oct 11. Cancer Immunol Immunother. 2019. PMID: 30311027 Free PMC article.
Treatment-related side effects and quality of life in cancer patients.
Mazzotti E, Antonini Cappellini GC, Buconovo S, Morese R, Scoppola A, Sebastiani C, Marchetti P. Mazzotti E, et al. Among authors: antonini cappellini gc. Support Care Cancer. 2012 Oct;20(10):2553-7. doi: 10.1007/s00520-011-1354-y. Epub 2012 Jan 21. Support Care Cancer. 2012. PMID: 22270087
Reduction of T Lymphoma Cells and Immunological Invigoration in a Patient Concurrently Affected by Melanoma and Sezary Syndrome Treated With Nivolumab.
Narducci MG, Tosi A, Frezzolini A, Scala E, Passarelli F, Bonmassar L, Monopoli A, Accetturi MP, Cantonetti M, Antonini Cappellini GC, De Galitiis F, Rosato A, Picozza M, Russo G, D'Atri S. Narducci MG, et al. Among authors: antonini cappellini gc. Front Immunol. 2020 Sep 25;11:579894. doi: 10.3389/fimmu.2020.579894. eCollection 2020. Front Immunol. 2020. PMID: 33072126 Free PMC article. Clinical Trial.
Circulating miR-1246 and miR-485-3p as Promising Biomarkers of Clinical Response and Outcome in Melanoma Patients Treated with Targeted Therapy.
Levati L, Bassi C, Mastroeni S, Lupini L, Antonini Cappellini GC, Bonmassar L, Alvino E, Caporali S, Lacal PM, Narducci MG, Molineris I, De Galitiis F, Negrini M, Russo G, D'Atri S. Levati L, et al. Among authors: antonini cappellini gc. Cancers (Basel). 2022 Jul 29;14(15):3706. doi: 10.3390/cancers14153706. Cancers (Basel). 2022. PMID: 35954369 Free PMC article.
Association of CTLA-4 Gene Variants with Response to Therapy and Long-term Survival in Metastatic Melanoma Patients Treated with Ipilimumab: An Italian Melanoma Intergroup Study.
Queirolo P, Dozin B, Morabito A, Banelli B, Piccioli P, Fava C, Leo C, Carosio R, Laurent S, Fontana V, Ferrucci PF, Martinoli C, Cocorocchio E, Battaglia A, Ascierto PA, Capone M, Simeone E, De Galitiis F, Pagani E, Antonini Cappellini GC, Marchetti P, Guida M, Tommasi S, Mandalà M, Merelli B, Quaglino P, Fava P, Guidoboni M, Romani M, Spagnolo F, Pistillo MP. Queirolo P, et al. Among authors: antonini cappellini gc. Front Immunol. 2017 Apr 12;8:386. doi: 10.3389/fimmu.2017.00386. eCollection 2017. Front Immunol. 2017. PMID: 28446908 Free PMC article.
Corrigendum: Association of CTLA-4 Gene Variants with Response to Therapy and Long-term Survival in Metastatic Melanoma Patients Treated with Ipilimumab: An Italian Melanoma Intergroup Study.
Queirolo P, Dozin B, Morabito A, Banelli B, Piccioli P, Fava C, Leo C, Carosio R, Laurent S, Fontana V, Ferrucci PF, Martinoli C, Cocorocchio E, Battaglia A, Ascierto PA, Capone M, Simeone E, De Galitiis F, Pagani E, Antonini Cappellini GC, Marchetti P, Guida M, Tommasi S, Mandalà M, Merelli B, Quaglino P, Fava P, Guidoboni M, Romani M, Spagnolo F, Pistillo MP. Queirolo P, et al. Among authors: antonini cappellini gc. Front Immunol. 2018 Mar 2;9:403. doi: 10.3389/fimmu.2018.00403. eCollection 2018. Front Immunol. 2018. PMID: 29531523 Free PMC article.
24 results